Skip to main content

Table 1 Baseline characteristics of patients enrolled in the study (n = 83)

From: The safety and efficacy of sequential intramuscular/oral ziprasidone treatment of acute episode in patients with schizophrenia: a multicenter, open-labeled study

Age (years)

32.06 ± 10.06 (18 – 59)

Gender (Male: Female)

41:42

Weight, kg

 Mean ± SD

67.81 ± 13.31

 Range

45 – 103

Height, cm

 Mean ± SD

168.59 ± 6.84

 Range

157 – 183

BMI

 Mean ± SD

23.68 ± 3.84

 Range

15.90 – 37.11

Duration of schizophrenia, years

 Mean ± SD

5.83 ± 5.59

 Range

0 – 29

PANSS

 Mean ± SD

90.87 ± 15.66

 Range

51 – 125

Positive PANSS subscale

 Mean ± SD

26.78 ± 4.35

 Range

16 – 37

Negative PANSS subscale

 Mean ± SD

19.07 ± 8.13

 Range

7 – 38

General psychopathology subscale

 Mean ± SD

45.01 ± 7.71

 Range

21 – 62

PANSS-EC

 Mean ± SD

19.52 ± 4.26

 Range

8 – 32

CGI

 Mean ± SD

5.55 ± 0.70

 Range

4 – 7

BARS

 Mean ± SD

5.82 ± 0.83

 Range

5 – 7

Heart rate (HR)

 Mean ± SD

84.53 ± 11.95

 Range

68 – 130

Systolic blood pressure, mmHg

 Mean ± SD

121.24 ± 13.81

 Range

100 – 156

Diastolic blood pressure, mmHg

 Mean ± SD

77.49 ± 8.79

 Range

56 – 96

Temperature, ℃

 Mean ± SD

36.47 ± 0.23

 Range

36 – 37.2

QTc interval of ECG

 Mean ± SD

376.18 ± 41.17

 Range

279 – 449

  1. BMI Body Mass Index, PANSS Positive and Negative Syndrome Scale, PANSS-EC Excited Component of PANSS, CGI the Clinical Global Impressions scale, BARS the Behavioral Activity Rating Scale